EMB offers diversified exposure to USD-denominated emerging market sovereign and agency bonds, with a balanced mix of investment-grade and high-yield issuances. The ETF provides higher yields than US Treasuries and may serve as a hedge against localized inflation and rate policy, but not against US inflation. Risks include significant exposure to below-investment-grade debt, potential fiscal challenges from US tariffs, and heightened political and economic uncertainties in emerging markets.

ConocoPhillips is expanding its LNG business. Its stake in the Port Arthur LNG project position it well to benefit from the recent U.S./EU trade deal. COP's integrated LNG value chain, proprietary technology, and global partnerships give it unique size-and-scale and competitive advantages in the global LNG market. Nearer-term, COP's Q2 earnings (due out August 7) will be more impactful, while potential sale of Anadarko assets would support debt reduction and portfolio optimization.

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)

DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company's innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.

LOUISVILLE, K.Y., July 30, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended June 30, 2025 before the market open on Wednesday, August 13, 2025. A conference call to review the results is scheduled for Wednesday, August 13, 2025, at 9:00 am Eastern Time, which will include prepared remarks and materials from management followed by a live Q&A. The call will be hosted by Rick Mills, Chairman and Chief Executive Officer, …

Record 129 Net New Openings in Second Quarter, 19.8% Net New Unit Growth DALLAS , July 30, 2025 /PRNewswire/ -- Wingstop Inc. ("Wingstop" or the "Company") (NASDAQ: WING) today announced financial results for the fiscal second quarter ended June 28, 2025. Highlights for the fiscal second quarter 2025 compared to the fiscal second quarter 2024: System-wide sales increased 13.9% to $1.3 billion 129 net new openings in the fiscal second quarter 2025 Domestic restaurant AUV increased to $2.1 million Domestic same store sales decreased 1.9% Digital sales increased to 72.2% of system-wide sales Total revenue increased 12.0% to $174.3 million …

Second Quarter 2025 Consumer Credit Trends Indicate Bank Card Delinquencies Continuing Downward Trend ATLANTA , July 30, 2025 /PRNewswire/ -- Equifax ® (NYSE: EFX) has released its Market Pulse Second Quarter U.S. Consumer Credit Trends , which includes U.S. national consumer credit data and trends through June 2025 sourced from Equifax data. According to Equifax, delinquency on total U.S. consumer debt was 1.5% in June, steady from 1.5% in May and April, marking a 0.2% increase from the end of the first quarter of 2025.

Zoomcar expands Home Delivery to 14 cities with smarter, seamless fulfillment BANGALORE, India , July 30, 2025 /PRNewswire/ -- Zoomcar (OTCQX: ZCAR), India's largest peer-to-peer car sharing marketplace, has significantly expanded and strengthened its Home Delivery proposition to enhance Guest convenience and boost Host earnings. Through a dual approach, a revamped Host Delivery construct and partnerships with trusted third-party driver platforms, Zoomcar is ensuring that more cars than ever before can be delivered directly to Guests' doorsteps.

STRASBURG, Va., July 30, 2025 (GLOBE NEWSWIRE) -- First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported earnings for the quarter ended June 30, 2025 of $5.05 million and basic and diluted earnings per common share of $0.56.

NORWELL, Mass.--(BUSINESS WIRE)--Clean Harbors, Inc. (“Clean Harbors” or the “Company”) (NYSE: CLH), the leading provider of environmental and industrial services throughout North America, today announced financial results for the second quarter ended June 30, 2025. “Our second-quarter results reflect the consistent profitable growth of our Environmental Services (ES) segment, where we experienced strong demand for our disposal assets, and a stabilization of our Safety-Kleen Sustainability Solu.

EVERETT, Wash.--(BUSINESS WIRE)--Fortive Corporation (“Fortive”) (NYSE: FTV) today announced financial results for the second quarter of 2025. “The second quarter of 2025 was pivotal for Fortive,” said Olumide Soroye, President and CEO. “We completed our spin-off of Ralliant and launched a new chapter at Fortive with a clear value creation plan to accelerate profitable growth and enhance shareholder returns. Despite uncertainty related to trade, healthcare and government spending policy impacti.

ARLINGTON, Va.--(BUSINESS WIRE)--Leonardo DRS, Inc. (Nasdaq: DRS), a leading provider of advanced defense technologies, today reported financial results for the second quarter 2025, which ended June 30, 2025. CEO Commentary “Leonardo DRS delivered another set of strong financial results marked by healthy bookings, solid organic revenue growth and continued profit and margin expansion in the second quarter. The need to deter and contest heightened global threats continues to bolster customer dem.

BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron's PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.

DALLAS--(BUSINESS WIRE)--Thryv Holdings, Inc. (NASDAQ:THRY) (“Thryv” or the “Company”), the provider of Thryv®, the leading small business marketing and sales software platform, reported an increase in SaaS revenue of 48% year-over-year and achieved record SaaS Adjusted EBITDA margin in the second quarter of 2025. Second Quarter Financial 2025 Highlights: SaaS revenue was $115.0 million, a 48% increase year-over-year SaaS revenue excluding Keap was $97.3 million, a 25% increase year-over-year M.

MIAMI--(BUSINESS WIRE)---- $REAX #therealbrokerage--Top-ranked JBRE & Co., joins Real, strengthening the company's presence in Arizona; Real now exceeds 29,000 agents throughout the U.S. and Canada.

Dividends are a powerful tool for building wealth and achieving financial independence, as highlighted by Rockefeller and Buffett. Most Americans, especially median and low-income earners, face a significant retirement savings gap and risk relying solely on Social Security. Chasing the highest-yielding dividend stocks can lead to poor investment outcomes, including dividend cuts and capital losses.

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases MIAMI, FLORIDA / ACCESS Newswire / July 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data showing that its topical Ketamir-2 cream delivered similar and consistent pain relief compared with injected morphine in a validated animal model of acute and inflammatory pain. In the study, Ketamir-2 cream was applied topically to …

Record Gross Profit Margins & Expanded Operating Margins Amidst A2L Product Transition; Strong Balance Sheet Fortifies the Company and Enables Continued Investments in Growth

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell's precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.